GHENT, Belgium,  28 February  2013  - Ablynx  [Euronext Brussels:  ABLX],  the 
biopharmaceutical  company  focused  on  the  discovery  and  development   of 
Nanobodies®, announces  today  that it  has  raised €31.5  million  through  a 
private placement  of new  shares via  an accelerated  bookbuilding  procedure 
announced on Wednesday 27 February 2013 after the market closed.

The private placement has allowed Ablynx to place 4,377,919 new shares with  a 
range of  domestic and  international  institutional investors  and  qualified 
institutional buyers in the United States at a price of €7.2 per share, a 6.7%
discount on the previous closing price.  This represents 10.0% of the  current 
number of outstanding shares and will  bring the total number of shares  after 
the issue to 48,157,116. The  new shares will be  admitted to trading on  NYSE 
Euronext Brussels following their issuance, which is expected to take place on
5 March 2013.

The private placement was oversubscribed and certain pre-IPO shareholders  and 
warrant holders sold 1,872,081  shares at the same  price in conjunction  with 
this transaction.

The funds will be used by Ablynx to:

  *maintain the momentum of ALX-0061  and review paths (e.g.  co-development, 
    fund additional  clinical trials,  retain  (co-) promotion  rights)  which 
    could allow the value of this asset to be maximized;
  *allow flexibility in the  structure and timing of  any potential deals  to 
    license clinical  assets  such  as caplacizumab  (anti-vWF)  and  ALX-0171 
  *initiate, advance  and/or  accelerate  the  pre-clinical  development  for 
    wholly-  and  co-owned  programmes  with  a  broad  range  of  risk-return 
    profiles; and
  *for general corporate purposes.

KBC Securities  NV acted  as  Global Coordinator.  KBC Securities  NV,  Bryan, 
Garnier &  Co. Limited  and  Nomura Code  Securities  Limited acted  as  Joint 
Bookrunners for the placement.

Dr Edwin Moses, Chairman and CEO of Ablynx commented:

"We are very  pleased to  announce the  successful completion  of the  private 
placement which we believe  reflects the strong progress  made at Ablynx  over 
the past year. The new funds will  give us increased flexibility to invest  in 
our Nanobody pipeline and  in particular to build  on the successful Phase  II 
results of our rheumatoid arthritis product, ALX-0061, announced earlier  this 
month. We  are grateful  to  our existing  shareholders for  their  continuing 
support and welcome our new investors.  We believe that Ablynx is well  placed 
to deliver significant value to shareholders  in the coming years and we  look 
forward to updating them on our progress during 2013."

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies^®, a novel class of therapeutic proteins based on  single-domain 
antibody  fragments,  for  a  range  of  serious  human  diseases,   including 
inflammation, haematology, oncology and pulmonary disease. Today, the  Company 
has approximately  25  programmes  in  the pipeline  and  five  Nanobodies  at 
clinical development  stage. Ablynx  has ongoing  research collaborations  and 
significant  partnerships  with   major  pharmaceutical  companies   including 
Boehringer Ingelheim, Merck Serono,  Novartis and Merck &  Co. The Company  is 
headquartered  in  Ghent,   Belgium.  More   information  can   be  found   on 

For more information, please contact

Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
 +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
e: ablynx@mcomgroup.com

Press release in pdf format


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Ablynx via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.